CCO Oncology Podcast

189 Épisodes

1. Treatment Options for Patients With Multiple Myeloma After First Relapse

   Publié: 14/07/2021
2. Precision Medicine in Gynecologic Cancers: Expert Answers to Your Questions

   Publié: 12/07/2021
3. Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas

   Publié: 12/07/2021
4. Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer

   Publié: 30/06/2021
5. Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions

   Publié: 29/06/2021
6. Expert Insight on Key Data From ASCO 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

   Publié: 24/06/2021
7. Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions

   Publié: 17/06/2021
8. Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer

   Publié: 19/05/2021
9. Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

   Publié: 18/05/2021
10. Immunotherapy for Advanced HCC: Case Series

    Publié: 17/05/2021
11. Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany

    Publié: 13/05/2021
12. Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond

    Publié: 04/05/2021
13. Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

    Publié: 28/04/2021
14. Expert Answers to Questions on Contemporary Management of Multiple Myeloma

    Publié: 22/04/2021
15. Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates

    Publié: 19/04/2021
16. Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer

    Publié: 15/04/2021
17. Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer

    Publié: 06/04/2021
18. Expert Answers to Questions on PARP Inhibition for Prostate Cancer

    Publié: 06/04/2021
19. Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL

    Publié: 26/03/2021
20. Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards

    Publié: 25/03/2021